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Reply to Gagnon et al.
From the Authors:
We thank Dr. Gagnon and colleagues for their interest and
comments. Because of the constraints of a research letter, we were not
able to provide all the details of the telehealth intervention. Brieﬂy,
each video session was designed to mimic the components of center-
based pulmonary rehabilitation (PR) and lasted 45 to 60minutes. The
sessions included stretching and breathing exercises for
approximately 10 minutes; aerobic exercises using a foot peddler or
walking for 10 and 20 minutes in those with low and high baseline
functional capacity, respectively; and strength training with stretch
bands for 10minutes. Educational sessions were interspersed between
these exercise periods. We agree with Dr. Gagnon and colleagues that
the interval between the initiation of PR and 30 days is short, and thus
we may not see meaningful changes in functional capacity. The 30-
day time point was chosen based on our primary outcome of hospital
readmission (1). We disagree that the higher proportion of patients
on domiciliary oxygen in the group exposed to PR may have
contributed to improved outcomes, as this suggests more severe and
perhaps less-responsive disease. We acknowledge that the study was
not randomized and that we did not collect data on the number of
patients approached and reasons for patient refusal to participate.
These limitations in part underlie our call for well-conducted
randomized trials to test the efﬁcacy of our intervention. They also
make a case that behavioral changes could have had a signiﬁcant
impact. Although we did not systematically study this in both
groups, the emotional guardedness domain of the psychosocial risk
factor survey did improve with telehealth PR (2). n
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The Controversies and Difﬁculties of Diagnosing
Primary Ciliary Dyskinesia
To the Editor:
We welcome the correspondence from Lavie and Amirav
(1), highlighting the difﬁculties diagnosing primary ciliary
dyskinesia (PCD) and the role of high-speed video analysis
(HSVA). As members of the European Respiratory
Society (ERS) PCD Diagnostic Task Force (2) and/or large
PCD Centres, we agree that HSVA has an important role
that is not recognized by the American Thoracic Society
(ATS) PCD Diagnostic Guideline (3). This risks a large
This article is open access and distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives License 4.0
(http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage
and reprints, please contact Diane Gern (dgern@thoracic.org).
Supported by NIH grant K23HL133438 (S.P.B.).
Originally Published in Press as DOI: 10.1164/rccm.201907-1486LE on
August 6, 2019
This article is open access and distributed under the terms of the Creative
Commons Attribution Non-Commercial No Derivatives License 4.0
(http://creativecommons.org/licenses/by-nc-nd/4.0/). For commercial usage
and reprints, please contact Diane Gern (dgern@thoracic.org).
Author Contributions: A.S. and J.S.L. provided the concept and drafted the
correspondence; all authors commented and approved the manuscript.
The authors are members of European Respiratory Society Task Force (TF-
2014-04) and BEAT-PCD network (COST Action BM 1407).
Originally Published in Press as DOI: 10.1164/rccm.201907-1334LE on
August 21, 2019
CORRESPONDENCE
120 American Journal of Respiratory and Critical Care Medicine Volume 201 Number 1 | January 1 2020
proportion of false-negative “missed” diagnoses and a sizable
number of false-positive cases; we make additional important
observations.
We agree with Lavie and Amirav that nasal nitric oxide
(nNO) should not be used in isolation to make a diagnosis or
to exclude PCD. The risk for false-negatives is clearly described
in the literature (reviewed in Reference 2). The ERS Guidelines
therefore suggest that both nNO and HSVA should be entirely
normal before deciding that further investigation is not
warranted (2). We all have patients who proceeded to further
testing because clinical history was strong or HSVA was
abnormal despite normal nNO, and then had a diagnosis
conﬁrmed by transmission electron microscopy (TEM) or
genetics (e.g., CCDC103, DNAH9, or RSPH1 mutations).
Contrary to Lavie and Amirav, neither ATS nor ERS guidelines
would exclude the diagnosis of PCD in patients with a
compatible history and diagnostically low nNO despite normal
HSVA, without proceeding to further tests including TEM
and genetics.
Similarly to Lavie and Amirav, we were surprised that the
ATS guideline speciﬁcally suggests not assessing ciliary beat
pattern. Dyskinesia is a key feature of the condition and
can be accurately detected by HSVA (4). According to the
ERS Guidelines, repeatedly dyskinetic cilia or abnormal
beat pattern following reanalysis after culture, with normal
genetics and TEM, indicates PCD is “highly likely” (2),
and patients should follow a PCD treatment plan (2).
This recognizes that TEM and genetics will each be normal
in 20–30% (2) of patients who truly have PCD (false
negative), and that HSVA will detect most of these patients
who require specialist PCD care. Until HYDIN, DNAH11, and
GAS8 were discovered as PCD genes, the patients were
recognized by abnormal HSVA, and until all genetic causes are
identiﬁed, HSVA is needed. It also acknowledges that even
repeatedly abnormal HSVA may be falsely positive, and
therefore the ERS Guidelines recommend that patients are not
labeled as deﬁnitely having PCD based on HSVA alone (2, 4).
Importantly, HSVA provides an accurate result on the
day of testing that can be used to counsel patients and
commence treatment while awaiting conﬁrmatory TEM
and genetics (4). HSVA also has an important research
value, assessing the ability of novel treatments to restore
function.
There are a large number of PCD genes, and because
of their size, variants are common; not infrequently,
patients without PCD have biallelic variants of unknown
signiﬁcance in PCD-related genes. The speciﬁcity of genetic
testing is severely reduced, and many individuals could
be incorrectly diagnosed with PCD (false positive) unless
the mutations are conﬁrmed pathogenic. It is therefore
essential to ensure that the genotype is compatible with
the ciliary phenotype using HSVA, TEM, and/or
immunoﬂuorescence labeling, as well as with the clinical
phenotype (2).
Importantly, there is no perfect way to identify
patients for diagnostic testing based on clinical assessment.
Lavie and Amirav outline the approach proposed by the ATS
Guideline, using a four-point clinical symptoms score.
Having two of four clinical features provides speciﬁcity
(0.72), ensuring that the diagnostic service only sees the
most likely cases, but we suggest it has insufﬁcient sensitivity
for screening (0.8), meaning that 20% of patients with
PCD are not tested and will therefore never be correctly
diagnosed (5). The ERS Guideline provides a ﬂexible
approach (“patients with several typical features” [2]), or
suggests a clinical predictive score called Primary Ciliary
Dyskinesia Rule (PICADAR), which has good sensitivity and
speciﬁcity (cutoff, 4; 0.97, speciﬁcity, 0.48) (6). Therefore,
PICADAR may correctly identify 97% of patients who require
further testing, while not inappropriately overwhelming
diagnostic services, as approximately 50% of patients will turn
out to have PCD. Both scores need validating in primary
care settings. n
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High-Speed Videomicroscopy Analysis Presents
Limitations in Diagnosis of Primary Ciliary Dyskinesia
To the Editor:
In response to the letter by Dr. Lavie and Dr. Amirav highlighting
the use of high-speed videomicroscopy analysis (HSVA) in a patient
with suspected primary ciliary dyskinesia (PCD) (1), we stand
by the American Thoracic Society (ATS) PCD diagnostic guideline
recommendation. This recommendation speciﬁcally states that
clinicians should avoid using HSVA as a replacement diagnostic
test for transmission electron microscopy (TEM) and/or extended
genetic panel testing (2). Although we appreciate the authors’
opinion and argument for the use of HSVA as a diagnostic tool in
PCD, we have concerns about their anecdotal evidence and
reference to publications with methodologic bias.
First, they reference a publication reporting near-perfect
sensitivity and speciﬁcity of HSVA testing for PCD (3). In
this article, randomly selected HSVA case interpretations from
blinded experts, at three separate centers in England, are
retrospectively analyzed for diagnostic accuracy. This
publication has numerous methodologic biases (explained in a
recently published letter [4]) that affect data interpretation
and likely inﬂate the diagnostic accuracy. No other
publication has examined the diagnostic accuracy of HSVA
against PCD genetic testing. Thus, the true diagnostic
accuracy of HSVA in the era of PCD genomics remains
unclear, but it is likely lower than the values described in that
article.
No single diagnostic test can exclude PCD. TEM and genetic
testing individually miss approximately 30% of PCD diagnoses.
The authors claim that in one case, normal HSVA “helped to
determine a diagnosis of PCD in this patient as being highly
unlikely,” even though the patient had a strong PCD phenotype
and repeatedly low nasal nitric oxide (nNO) values. Defects in at
least six known PCD-associated genes (HYDIN, CCDC164,
DNAH9, GAS8, CCNO, and MCIDAS) result in normal or
nondiagnostic HSVA, and more common genes (DYX1C1,
RSPH1, and RSPH4A) have unexpected beat patterns for their
corresponding axonemal defects, making HSVA nondiagnostic in
these cases as well. Despite the well-recognized possibility of
PCD with normal HSVA, the authors do not present any TEM or
genetic testing results in their case and dismiss this patient from
further PCD therapies. Their decision to ignore the repeatedly
low nNO values as a consequence of sinus surgeries is
concerning, as nNO levels typically increase in non-PCD
patients after sinus surgery (5). The ATS PCD guidelines were
prioritized to avoid this scenario, in which patients with PCD
are dismissed because of false-negative results on a single
diagnostic test.
Finally, the authors claim the “simplicity of use and
expeditious results” of HSVA should prompt the ATS to
reconsider its PCD diagnostic guidelines. However, there is
nothing simple about HSVA studies, as they remain
nonstandardized in both sample preparation and beat pattern
interpretation. Moreover, to avoid secondary causes of
dyskinesia giving false-positive results, the European Respiratory
Society PCD guidelines also strongly recommend regrowth of
ciliary samples at the air–liquid interface before HSVA
analysis (6). This arduous, weeks-long regrowth process
requires highly specialized laboratory expertise and refutes the
claim of “expeditious results,” leading to an immediate PCD
diagnosis. Most important, no studies have shown that HSVA
can be reliably and accurately performed outside of a few expert
centers (2).
The ATS PCD diagnostic guidelines are rooted in science with
rigorous methodology. Although not perfect, they represent the
most rigorous review and analysis of scientiﬁc publications on
PCD diagnosis and prioritize limiting false-negative diagnoses in
which patients will suffer without proper, long-term PCD
therapies. Until prospective, well-designed, multicenter studies
are completed, the ATS guideline committee cannot recommend
HSVA as a clinical diagnostic test for PCD. n
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